Table 2.
Quality of life (QOL) in lymphovenous bypass (LVB) using ad-hoc tools.
| Study | Year Published | Number of Patients | Stage | Lymphedema Site | Primary vs. Secondary | Surgical Procedure | Baseline QOL Measure Administered Pre-Operatively? | Average Follow-Up Time | QOL Measure | Percent of Patients with Subjective Improvement |
|---|---|---|---|---|---|---|---|---|---|---|
| O’Brien | 1990 | 52 | Not mentioned | UE (46), LE (6) | Secondary | LVB | Not mentioned | 4.2 mo | Ad-hoc tool | 73% |
| Demirtas et al. | 2009 | 42 | Campisi stage II (12), III (17), IV (13) | LE | Secondary (34), Primary (8) | LVB | Not mentioned | 11.8 mo | Ad-hoc tool | 95% |
| Chang | 2010 | 20 | Capisi stage II (10), III (10) | UE (20) | Secondary | LVB | Yes | 12 mo | Ad-hoc tool | 80% |
| Auba et al. | 2012 | 10 | Campisi stage II (2), III (8) | LE (4), UE (6) | Secondary (9), Primary (1) | LVB | No | 18 mo | Ad-hoc tool | 90% |
| Mihara et al. | 2012 | 6 | ISL 0 (3), 1 (3) | LE | Secondary | LVB | Yes | 6 mo | Ad-hoc tool | 100% |
| Ayestaray et al. | 2013 | 20 | Campisi stage II (9), III (7), IV (3), V (1) | UE | Not mentioned | LVB | Yes | 6 mo | Ad-hoc tool | 95% |
| Chang et al. | 2013 | 100 | ICG classification stage 1 or 2 (16), 3 or 4 (14). Not all patients classified | UE (89), LE (11) | Secondary | LVB | Not mentioned | 30.4 mo (UE), 18.2 mo (LE) | Ad-hoc tool | 96% (UE), 57% (LE) |
| Mihara et al. | 2016 | 84 | ISL 1 (30), 2a (39), 2b (36), 3 (23) | LE | Primary (15), Secondary (69) | LVB | Yes | 18.3 mo | Ad-hoc tool | 80% |
| Chen et al. | 2016 | 21 | Campisi I and II (9), III (4), IV (8) | UE (13), LE (8) | Primary (4), Secondary (17) | LVB (18) or VLNT (3) | Yes | 12 mo | Ad-hoc tool | 100% |
| Masia et al. | 2016 | 200 | Not mentioned | UE (200) | Secondary (200) | LVB (81), VLNT (7), DIEP/SIEA with groin lymph nodes (16), LVB+VLNT (44), liposuction (52) | Yes | 12 mo | Ad-hoc tool | 96% |
| Poumellec et al. | 2017 | 31 | Campisi stage 2 (18), 3 (10), 4 (3) | UE | Secondary | LVB | Yes | 12.7 mo | Ad-hoc tool | 84% |
| Chung et al. | 2019 | 18 | Campisi stage II (7), III or IV (11) | UE (8), LE (10) | Secondary | LVB | No | 6 mo | Ad-hoc tool | Individual patient data not reported |
ISL, international society of lymphology; UE, upper extremity; LE, lower extremity; LVB, lymphovenous bypass; VLNT, vascularized lymph node transplant; DIEP, deep inferior epigastric perforator flap; SIEA, superficial inferior epigastric perforator flap; mo, months.